Market Research Logo

Global Factor VIII Deficiency Treatment Market 2017-2021

Global Factor VIII Deficiency Treatment Market 2017-2021

About Factor VIII

Factor VIII is an essential blood-clotting protein, which is also known as an antihemophilic factor. In individuals, factor VIII is encoded by F8 gene. Defects in F8 gene lead to hemophilia A, a recessive X-linked coagulation disorder. Factor VIII is generated in liver sinusoidal cells and endothelial cells outside the liver across the body. This protein mixes in the bloodstream in an inactive form, and binds to another molecule called von Willebrand factor, until a damage to blood vessels occur. In response to injury, coagulation factor VIII gets activated and separates from von Willebrand factor.

Technavio’s analysts forecast the global factor VIII market to grow at a CAGR of 5.59% during the period 2017-2021.

Covered in this report

The report covers the present scenario and the growth prospects of the global factor VIII market for 2017-2021. To calculate the market size, the report considers the global demand for factor VIII.

The market is divided into the following segments based on geography:

  • Americas
  • APAC
  • EMEA
Technavio's report, Global Factor VIII Market 2017-2021, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

Key vendors
  • Bayer HealthCare
  • CSL
  • Grifols
  • Novo Nordisk
  • Pfizer
  • Shire
Other prominent vendors
  • Alnylam Pharmaceuticals
  • Amarna Therapeutics
  • Asklepios BioPharmaceutical
  • Biogen Idec
  • BioMarin Pharmaceutical
  • Catalyst Biosciences
  • Chiesi Pharmaceutical
  • Dimension Therapeutics
  • Emergent BioSolutions
  • F. Hoffmann-La Roche
  • Kedrion
  • Octapharma
  • rEVO Biologics
  • OPKO Biologics
  • Sangamo Therapeutics
  • Spark Therapeutics
  • Swedish Orphan Biovitrum
  • uniQure
Market driver
  • Paradigm shift towards the development of drugs with extended half-life
  • For a full, detailed list, view our report
Market challenge
  • Low diagnosis rate affecting the market growth
  • For a full, detailed list, view our report
Market trend
  • Increasing investments of vendors to improve the production expertise
  • For a full, detailed list, view our report
Key questions answered in this report
  • What will the market size be in 2021 and what will the growth rate be?
  • What are the key market trends?
  • What is driving this market?
  • What are the challenges to market growth?
  • Who are the key vendors in this market space?
  • What are the market opportunities and threats faced by the key vendors?
  • What are the strengths and weaknesses of the key vendors?


  • Executive summary
  • Scope of the report
    • Market overview
    • Top-vendor offerings
      • Table Product offerings
  • Market research methodology
    • Research methodology
    • Economic indicators
  • Introduction
    • Key market highlights
    • Highlights
  • Deficiency overview
    • Table Process of gene therapy
    • Table Key buying criteria for global factor VIII deficiency treatment market 2016 and 2021
    • Table Key customer segments of factor VIII deficiency treatment market
  • Pipeline analysis
    • Table Pipeline analysis as of 2016
    • Table Key clinical trials
  • Market landscape
    • Market overview
      • Table Global factor VIII deficiency treatment market snapshot
      • Table Global factor VIII deficiency treatment market 2016-2021 ($ billions)
      • Table Global factor VIII deficiency treatment market by volume 2016-2021 (million units)
      • Table Impact of factors affecting the market 2016 and 2021
      • Table Opportunity analysis in global factor VIII deficiency treatment market
    • Five forces analysis
      • Table Five forces analysis
  • Market segmentation by type of disease application
    • Global hemophilia A drugs market
      • Table Global factor VIII therapy in hemophilia A market 2016-2021 ($ millions)
    • Global hemophilia A inhibitors treatment market
      • Table Global factor VIII therapy in hemophilia A inhibitors market 2016-2021 ($ millions)
    • Global von Willebrand disease treatment market
      • Table Global factor VIII therapy in von Willebrand disease treatment market 2016-2021 ($ millions)
  • Market segmentation by type of therapy
    • Recombinant therapies
      • Table Recombinant therapies in global factor VIII deficiency treatment market 2016-2021 ($ billions)
    • Plasma-derived therapies
      • Table Plasma-derived therapies in global factor VIII deficiency treatment market 2016-2021 ($ billions)
  • Market segmentation by type of disease management
    • Table Segmentation of factor VIII drugs market by type of disease management based on revenue 2016
    • Prophylaxis
    • On-demand therapy
    • Inhibitor therapy
  • Geographical segmentation
    • Table Segmentation of global factor VIII deficiency treatment market based on geography 2016 and 2021
    • Table Factor VIII deficiency treatment market revenue by geography 2016-2021 (%)
    • Factor VIII deficiency treatment market in Americas
      • Table Market scenario in Americas
      • Table Factor VIII deficiency treatment market in Americas 2016-2021 ($ billions)
    • Factor VIII deficiency treatment market in EMEA
      • Table Market scenario in EMEA
      • Table Factor VIII deficiency treatment market in EMEA 2016-2021 ($ billions)
    • Factor VIII deficiency treatment market in APAC
      • Table Market scenario in APAC
      • Table Factor VIII deficiency treatment market in APAC 2016-2021 ($ billions)
  • Market drivers
    • Increasing adoption of prophylactic drugs
    • Paradigm shift toward the development of drugs with extended half-life
    • Large patient pool driving the shipments of factor VIII units
      • Table Incidence rates of factor VIII deficiency
      • Table YoY shipments of factor VIII units 2012-2016 (million units)
  • Impact of drivers
    • Table Impact of drivers
  • Market challenges
    • Low diagnosis rate affecting the market growth
      • Table Diagnosis and treatment trends of hemophilia A 2013
      • Table Percentage share of diagnosed and undiagnosed hemophilia population 2012-2016
    • High entry barriers
    • Cost-intensive complex treatment
      • Table Forcefield analysis of drivers and challenges
  • Impact of drivers and challenges
    • Table Impact of drivers and challenges
  • Market trends
    • Increase in technological innovations
    • Development of gene therapy products
    • Expansion initiatives of vendors fueling the market growth
    • Increasing investments of vendors to improve the production capability
  • Vendor landscape
    • Competitive scenario
      • Table Competitive structure analysis of global factor VIII deficiency treatment market 2016
      • Table Competitive analysis of global factor VIII deficiency treatment market
      • Table Market share analysis 2016
      • Table Market penetration of various factor VIII manufacturers worldwide 2016
      • Table Strategic success factors of companies in global factor VIII deficiency treatment market
  • Key vendor analysis
    • Bayer HealthCare
      • Table Key highlights
      • Table Bayer HealthCare: Strength assessment
      • Table Bayer HealthCare: Strategy assessment
      • Table Bayer HealthCare: Opportunity assessment
      • Table Bayer HealthCare: YoY revenue and growth rate of Kogenate 2013-2015 ($ billions)
    • CSL
      • Table Key highlights
      • Table CSL: Strength assessment
      • Table CSL: Strategy assessment
      • Table CSL: Opportunity assessment
    • Grifols
      • Table Key highlights
      • Table Grifols: Strength assessment
      • Table Grifols: Strategy assessment
      • Table Grifols: Opportunity assessment
      • Table YoY growth rate and revenue of bioscience segment 2013-2015 ($ billions)
    • Novo Nordisk
      • Table Key highlights
      • Table Novo Nordisk: Strength assessment
      • Table Novo Nordisk: Strategy assessment
      • Table Novo Nordisk: Opportunity assessment
      • Table Novo Nordisk: YoY revenue and growth of hemophilia segment 2013-2015
    • Pfizer
      • Table Key highlights
      • Table Pfizer: Strength assessment
      • Table Pfizer: Strategy assessment
      • Table Pfizer: Opportunity assessment
      • Table Pfizer: YoY revenue and growth rate of Xyntha/ReFacto AF 2013-2015 ($ millions)
    • Shire
      • Table Key highlights
      • Table Shire: Strength assessment
      • Table Shire: Strategy assessment
      • Table Shire: Opportunity assessment
      • Table Baxalta: YoY revenue comparison of hemophilia segment 2013-2015 ($ billions)
      • Table Baxalta: Geographic segmentation of hemophilia by revenue 2015
    • Other prominent vendors
  • Appendix
    • List of abbreviation
  • Explore Technavio

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report